Recent Updates
Recently added Catalysts

KPI-121

Phase 3

Kerato Conjunctivitis Sicca | Small molecule | Other |KALA BIO, Inc.|Last Updated: Apr 2, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment901
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03616899Safety and Efficacy of KPI-121 in Subjects With DEDPHASE3 COMPLETED 901 — — Jul 10, 2018Feb 5, 2020Apr 2, 202181 United States, United States +79
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
PurposeTREATMENT
Interventions
NameTypeDescription
KPI-121 Ophthalmic SuspensionDRUGKPI-121 Ophthalmic Suspension
VehicleDRUGVehicle for KPI-121 0.25% ophthalmic suspension
Unlock Study Design Details